Detailansicht

Wissensnetz

Person

Martin Kortüm

Arzt

Name	Martin Kortüm
Zeit	2018- (Wirkungsdaten)
Ort	Würzburg (Wirkungsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf)
Variante	K. Martin Kortüm K. M. Kortüm M. Kortüm K. M. Kortuem
Beziehung	Universitätsklinikum Würzburg (Inhaber des Lehrstuhls für Translationale Myelomforschung) Plasmozytom (Thema)
Quelle	ResearchGate: https://www.researchgate.net/profile/Kmartin-Kortuem (Stand: 26.04.2024) https://www.ukw.de/medizinische-klinik-ii/haematologie/team/haematologie-detail/name/kortuem-martin/ (Stand: 26.04.2024)
Datensatztyp	Person
GND-Nummer	1268248770
Datensatz-ID	1268248770
Beteiligt an alle anzeigen Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome Real-world analysis of teclistamab in 123 RRMM patients from Germany Modellierung klonaler Evolution beim Multiplen Myelom Quantitative Analyse histologischer Aufnahmen der Haut Real world M³P Panel-Sequenzierung für die personalisierte Therapie des Multiplen Myeloms Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis — a clinical feasibility study Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1 Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma 18F-Fluordesoxyglucose- und 11C-Methionin-PET/CT bei Patient/-innen mit neu diagnostiziertem Multiplen Myelom: Ein Vergleich volumenbasierter PET-Biomarker CXCR4-directed imaging and endoradiotherapy in desmoplastic small round cell tumors The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma Die monoklonale Gammopathie (un) klarer Signifikanz 68Ga-pentixafor PET/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma Super-resolution microscopy of plasma membrane receptors Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab 18F-FDG and 11C-methionine PET/CT in newly diagnosed multiple myeloma patients: comparison of volume-based PET biomarkers 18F-FDG, 11C-methionine, and 68Ga-pentixafor PET/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement Exploration of artificial intelligence use with ARIES in multiple myeloma research The link between cytogenetics/genomics and imaging patterns of relapse and progression in patients with relapsed/refractory multiple myeloma: a pilot study utilizing 18F-FDG PET/CT Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy Diagnostische und therapeutische Betrachtungen zum Rezidiv des multiplen Myeloms : Eine aktuelle Übersicht Comparison of 11C-choline and 11C-methionine PET/CT in multiple myeloma Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy Spectrum and functional validation of PSMB5 mutations in multiple myeloma Moderne Diagnostik des multiplen Myeloms Multiples Myelom – Update 2018 European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma : : what to use and when The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma [Image of the Month]

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Martin Kortüm

Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

Real-world analysis of teclistamab in 123 RRMM patients from Germany

Modellierung klonaler Evolution beim Multiplen Myelom

Quantitative Analyse histologischer Aufnahmen der Haut

Real world M³P Panel-Sequenzierung für die personalisierte Therapie des Multiplen Myeloms

Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis — a clinical feasibility study

Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma

Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1

Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

18F-Fluordesoxyglucose- und 11C-Methionin-PET/CT bei Patient/-innen mit neu diagnostiziertem Multiplen Myelom: Ein Vergleich volumenbasierter PET-Biomarker

CXCR4-directed imaging and endoradiotherapy in desmoplastic small round cell tumors

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

Die monoklonale Gammopathie (un) klarer Signifikanz

68Ga-pentixafor PET/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms

Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease

Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression

Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma

Super-resolution microscopy of plasma membrane receptors

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

18F-FDG and 11C-methionine PET/CT in newly diagnosed multiple myeloma patients: comparison of volume-based PET biomarkers

18F-FDG, 11C-methionine, and 68Ga-pentixafor PET/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features

CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement

Exploration of artificial intelligence use with ARIES in multiple myeloma research

The link between cytogenetics/genomics and imaging patterns of relapse and progression in patients with relapsed/refractory multiple myeloma: a pilot study utilizing 18F-FDG PET/CT

Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy

Diagnostische und therapeutische Betrachtungen zum Rezidiv des multiplen Myeloms : Eine aktuelle Übersicht

Comparison of 11C-choline and 11C-methionine PET/CT in multiple myeloma

Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy

Spectrum and functional validation of PSMB5 mutations in multiple myeloma

Moderne Diagnostik des multiplen Myeloms

Multiples Myelom – Update 2018

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma : : what to use and when

The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma

The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma [Image of the Month]